Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 21;17(14):3936–3953. doi: 10.7150/ijbs.63732

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Effects of Lrp6 expression and silibinin treatment on the expression and activity of Cyp2e1. (A) Protein expression of Lrp6, β-catenin and Cyp2e1 among different treatment groups in mice. (B) Expression change of Lrp6, β-catenin and Cyp2e1 proteins by silibinin treatment between the Lrp6^(+/+) and the Lrp6^(+/-) mice. (C) Effects of Lrp6 genotypes and silibinin treatment on the activity of Cyp2e1 in mice received MCD diet. (D) The activity change of Cyp2e1 by silibinin treatment between the Lrp6^(+/+) and Lrp6^(+/-) mice. (E) Effects of Lrp6 expression on the expression changes of Lrp6, β-catenin and Cyp2e1 in HL7702 cells with and without oleat treatment. The cells were transfected with a control vector, the vectors containing Lrp6 siRNA or Lrp6 W. (F) The scheme showing that Lrp6 functional alteration confers different susceptibility to NAFLD and affects the therapeutic effect of silibinin by modulating Wnt/β-catenin-CYP2E1 signaling. * P < 0.05; ** P < 0.01; *** P < 0.001; NS, No significance.

Effects of Lrp6 expression and silibinin treatment on the expression and activity of Cyp2e1. (A) Protein expression of Lrp6, β-catenin and Cyp2e1 among different treatment groups in mice. (B) Expression change of Lrp6, β-catenin and Cyp2e1 proteins by silibinin treatment between the Lrp6^(+/+) and the Lrp6^(+/-) mice. (C) Effects of Lrp6 genotypes and silibinin treatment on the activity of Cyp2e1 in mice received MCD diet. (D) The activity change of Cyp2e1 by silibinin treatment between the Lrp6^(+/+) and Lrp6^(+/-) mice. (E) Effects of Lrp6 expression on the expression changes of Lrp6, β-catenin and Cyp2e1 in HL7702 cells with and without oleat treatment. The cells were transfected with a control vector, the vectors containing Lrp6 siRNA or Lrp6 W. (F) The scheme showing that Lrp6 functional alteration confers different susceptibility to NAFLD and affects the therapeutic effect of silibinin by modulating Wnt/β-catenin-CYP2E1 signaling. * P < 0.05; ** P < 0.01; *** P < 0.001; NS, No significance.